AstraZeneca Aktie News

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) posted what analysts called a very solid set of third-quarter results, but the shares barely moved in early morning trading as the City waited for more details on the analyst call.  In afternoon trading, shares in the giant drugmaker jumped over 4% to a new all time high above 12,990p.

AstraZeneca stock jumped Thursday after the drugmaker reported better-than-expected third-quarter sales and earnings.

CAMBRIDGE, England--(BUSINESS WIRE)--Q3 2025 Results Release.

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) posted a confident set of third-quarter results, not only beating revenue and core earnings forecasts, but also hailing "strong underlying momentum" across the business to set up growth through next year as well. The FTSE 100 pharmaceutical group generated revenues of $15.19 billion in the three months to 30 September, up 12% compared to a year ago and beat...

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to $15.19 billion from $13.57 billion.

AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of key cancer, heart and kidney disease drugs, prompting London's most valuable listed company to retain its full-year forecasts.

AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool.

AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool.